GlassScriptPhysician profile
Ramy Mansour
NPI 1134562549
$6,251.06
in general payments reported to CMS, 2019-2025
29 companies · $1,367 in 2025
The $1,367 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $39.60 · 2021: $526 · 2022: $732 · 2023: $1,267 · 2024: $1,903 · 2025: $1,367.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,463 · Education: $73.53.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,463.20 |
| Education | $73.53 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,281.79 | 2021-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $778.97 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Biotech, INC. | $592.21 | 2021-2025 | Stelara, Tremfya, Simponi Aria |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $478.69 | 2019-2025 | Xifaxan, Trulance |
| Regeneron Healthcare Solutions, INC. | $395.47 | 2022-2025 | Dupixent |
| Ironwood Pharmaceuticals, INC | $339.79 | 2020-2024 | Linzess |
| Celgene Corporation | $333.96 | 2021-2024 | Zeposia |
| Genzyme Corporation | $237.08 | 2023-2025 | |
| Ardelyx, INC. | $220.30 | 2022-2025 | Ibsrela |
| Pfizer INC. | $193.64 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $154.93 | 2021-2024 | Dificid |
| Boston Scientific Corporation | $154.14 | 2019 | |
| Lilly USA, LLC | $125.66 | 2024-2025 | Omvoh |
| Alexion Pharmaceuticals, INC. | $125.00 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $123.94 | 2024 | Zeposia |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $98.30 | 2024-2025 | Zenpep |
| Daiichi Sankyo INC. | $95.44 | 2022-2025 | Injectafer |
| Qol Medical, LLC | $93.02 | 2023-2025 | Sucraid |
| Fresenius Kabi USA, LLC | $87.12 | 2023 | Idacio |
| Gilead Sciences, INC. | $71.63 | 2019-2023 | |
| Nestle Healthcare Nutrition INC. | $60.08 | 2021-2023 | |
| Intercept Pharmaceuticals, INC. | $50.47 | 2024-2025 | |
| Celltrion USA INC. | $38.17 | 2025 | Vegzelma |
| Madrigal Pharmaceuticals | $34.64 | 2025 | Rezdiffra |
| Shield Therapeutics INC | $23.02 | 2023 | Accrufer |
| Lucid Diagnostics INC. | $18.64 | 2024 | |
| Organon LLC | $16.87 | 2023 | Hadlima, Renflexis |
| Evoke Pharma, INC. | $14.57 | 2023 | Gimoti |
| Braintree Laboratories, INC. | $13.52 | 2023 | Sutab |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ramy Mansour listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.